Oncology

The association between use of a telegenetics service and lower likelihood of germline testing was statistically significant among black veterans with cancer, according to a recent retrospective cohort study.

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.

Patients with human immunodeficiency virus and cancer may derive clinical benefit from immune checkpoint inhibition with no excess toxicity in non–small cell lung cancer and other cancers.

Arshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.

Preet M. Chaudhary, MD, and his medical team discuss graft-vs-host disease (GVHD) and their treatment experiences alongside a patient, Hector Cuevas.

Although findings from a population-based meta-analysis suggest a greater risk of death in patients due to cancers diagnosed during pregnancy and postpartum, not all disease sites had the same risk.

Co-editor-in-Chief Howard S. Hochster, MD, discusses persistent obstacles to the effective use of biosimilars in clinical practice.

The CAR T-cell product has a neoantigen-specific T-cell receptor that is located and classified via a T-cell receptor discovery platform.

Patients with curable metastatic cancer appear to have long-lasting improvements in depression symptoms 8 weeks after a single treatment with psilocybin therapy.

The safety profile of adagrasib monotherapy in advanced solid tumors harboring KRAS G12C mutations appears manageable, according to an expert from The University of Texas MD Anderson Cancer Center.

Fareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.

Findings from a prospective study suggest that circulating tumor DNA sequencing with a large panel may efficiently identify actionable alterations in patients with advanced solid tumors.

Lifestyle choices such as diet and exercise can be useful in managing symptom burden and may even have an impact on some treatment outcomes, according to a director of Lifestyle Medicine from Massachusetts General Hospital.

Data from a phase 1/2 dose escalation study investigating BDC-10001 plus nivolumab in HER2-expressing tumors support the advancement of additional phase 2 trials evaluating the novel antibody conjugate.

Findings from 2 phase 3 trials support the recommendation to approve sodium thiosulfate to reduce the risk of cisplatin-related hearing loss in pediatric patients with solid tumors in Europe.

Supporting data for the biologics license application for trastuzumab biosimilar HLX02 in HER2-overexpressing cancers come from comparative analytical studies and a global phase 3 trial.

The FDA’s decision to lift a partial clinical hold on the phase 1/2 VELA trial follows reports of visual adverse effects in patients with advanced solid tumors in February 2023.

Acceptance of an investigational new drug application for GRC 54276 will allow investigators to proceed with a phase 1/2 trial evaluating the agent in patients with advanced solid tumors and lymphomas.

Based on results from the phase 2 KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 trials, the FDA has given full approval to pembrolizumab for patients with microsatellite instability-high or mismatch repair deficient solid tumors.

Data from a prospective pilot study indicate that circulating tumor DNA may be a valuable prognostic biomarker in early-stage follicular lymphoma.

The safety profile of fam-trastuzumab deruxtecan-nxki for managing HER2-expressing tumors in the DESTINY-PanTumor02 trial appears consistent with previously reported findings on the agent.

Findings from the phase 3 DeFi trial support the new drug application for nirogacestat as a treatment for adults with desmoid tumors.

Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.

Rahul Banerjee, MD, FACP, recounts the recent Tandem meeting by highlighting an interesting study involving cell phones and cell therapies.

Adverse effects including light sensitivity and blurred vision lead to a clinical hold in enrollment for the phase 1/2 VERA trial evaluating BLU-222 in advanced solid tumors.